568 related articles for article (PubMed ID: 19451908)
21. Getting SMART (submission management and review tracking) drug review in the computer age.
Flieger K
FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
[TBL] [Abstract][Full Text] [Related]
22. The drive to reform the FDA gains momentum.
Gatty B
Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
[No Abstract] [Full Text] [Related]
23. Agency set up to tackle bioterror.
Wadman M
Nature; 2006 Dec; 444(7121):796-7. PubMed ID: 17167438
[No Abstract] [Full Text] [Related]
24. A dose of reality for the health watchdogs.
Kluger J
Time; 2001 Oct; 158(19):65-6. PubMed ID: 11699134
[No Abstract] [Full Text] [Related]
25. BIO and biogenerics.
Feldbaum CB
Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
[No Abstract] [Full Text] [Related]
26. Biodefense: 10 years after. Reinventing Project BioShield.
Cohen J
Science; 2011 Sep; 333(6047):1216-8. PubMed ID: 21885752
[No Abstract] [Full Text] [Related]
27. A gift to pharma?
Nat Med; 2005 Jul; 11(7):693. PubMed ID: 16015340
[No Abstract] [Full Text] [Related]
28. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
29. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
30. Vouchers for FDA priority reviews.
Spatz ID
Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
[No Abstract] [Full Text] [Related]
31. Notes and comments "High and dry?" The Public Readiness and Emergency Preparedness Act and liability protection for pharmaceutical manufacturers.
Copper BK
J Health Law; 2007; 40(1):65-105. PubMed ID: 17549932
[TBL] [Abstract][Full Text] [Related]
32. Old legacies and new paradigms: confusing "research" and "treatment" and its consequences in responding to emergent health threats.
Javitt GH
J Health Care Law Policy; 2005; 8(1):38-70. PubMed ID: 16538801
[No Abstract] [Full Text] [Related]
33. Drug development for neglected diseases - the trouble with FDA review vouchers.
Kesselheim AS
N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
[No Abstract] [Full Text] [Related]
34. Long wait almost over. Project Bioshield measure nears final approval.
Fong T
Mod Healthc; 2004 Jul; 34(29):18-9. PubMed ID: 15301143
[No Abstract] [Full Text] [Related]
35. Who pays what in drug development.
Love J
Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
[No Abstract] [Full Text] [Related]
36. Biodefense: spend, but spend wisely.
Green SK; Morin K
Am J Bioeth; 2005; 5(4):50-2. PubMed ID: 16109698
[No Abstract] [Full Text] [Related]
37. The FDA and congress: differing agendas?
Lipman AG
J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
[No Abstract] [Full Text] [Related]
38. Cost/success projections for US biodefense countermeasure development.
Matheny J; Mair M; Smith B
Nat Biotechnol; 2008 Sep; 26(9):981-3. PubMed ID: 18779804
[No Abstract] [Full Text] [Related]
39. Promoting public health and protecting consumers in a global economy: an overview of HHS/FDA's international activities.
Kelly DP; Bachorik LL
Food Drug Law J; 2005; 60(3):339-46. PubMed ID: 16304741
[No Abstract] [Full Text] [Related]
40. FDA performance goals for approving drugs and biologics.
Miller JD
JAMA; 2009 Jul; 302(2):189-91. PubMed ID: 19584348
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
